Avista Pharma Solutions Expands Drug Product cGMP Manufacturing at Colorado Site

World-class Facility to Formulate and Manufacture Extensive Range of
Dosage Forms

LONGMONT, Colo.–(BUSINESS WIRE)–Avista
Pharma Solutions, Inc. (“Avista Pharma”) has completed extensive
facility upgrades at its Longmont, Colorado site, expanding its drug
product manufacturing footprint by approximately 20,000 square feet and
allowing for the formulation and manufacture of new dosage forms. The
expansion includes four new, state-of-the-art cGMP processing suites and
all associated manufacturing support areas. These upgrades demonstrate
Avista Pharma’s commitment to delivering comprehensive, timely and
reliable service for all clients, regardless of their product’s stage in
the development lifecycle.

Avista Pharma’s drug product capabilities now include encapsulation;
high-shear granulation; fluid-bed granulation, drying and Wurster
coating; tablet compression; tablet coating; and packaging. In addition,
Avista Pharma’s drug product operations team now supports the
formulation and manufacture of the following dosage forms:

• Immediate-release tablets and capsules
• Enteric-release tablets
• Modified-release, multi-particulate tablets and capsules
• Hydrophilic and hydrophobic matrix extended-released tablets
• Opiate tamper-resistant, modified-release tablets (using a surrogate
  drug)
• Coated aqueous insoluble active ingredients

Complete with 24-hour environmental monitoring, the new manufacturing
suites are designed and monitored to ISO 7 requirements. The expanded
manufacturing support areas meet ISO 8 requirements and include a wash
and prep area, as well as clean equipment storage. The facility will
also include a new purified water system, walk-in stability storage
chambers and a temperature-controlled warehouse containing refrigerated
storage locations.

“Expanding our drug product capabilities enables us to better serve our
clients as a trusted, effective and innovative partner in all phases of
the drug development lifecycle,” said Ken Domagalski, General Manager of
the Longmont facility. “By offering optimized formulation and
manufacturing of a wider range of dosage forms, we can now help make
more life preserving medicines a reality.”

As part of Avista Pharma’s ongoing efforts to offer clients the most
efficient path to success, the company made several significant
investments in Longmont throughout 2017. In addition to strengthening
its drug product operations, Avista Pharma recently doubled the site’s
API manufacturing capacity.

NEW MEDIA CONTENT:

Avista Pharma on Facebook
https://www.facebook.com/AvistaPharma

Avista Pharma on Twitter
https://twitter.com/avistapharma

Avista Pharma on LinkedIn
https://www.linkedin.com/company/avista-pharma-solutions

ABOUT AVISTA PHARMA SOLUTIONS, INC.:

Avista Pharma Solutions is a contract development, manufacturing, and
testing organization that understands what it takes to rapidly advance
products through every stage of development. With over
200,000 square feet of laboratory and manufacturing space in the U.S., Avista
Pharma offers a broad suite of scientifically differentiated services
ranging from early stage discovery, API and Drug Product development and
cGMP manufacturing to stand-alone analytical and microbiology testing
support. Led by our broad experience and collaborative approach, we are
committed to finding the shortest, most efficient path to success for
our clients – success that goes beyond science. For more information on
how Avista Pharma can help your team succeed, please Contact
Us.

ABOUT AMPERSAND CAPITAL PARTNERS:

Founded in 1988, Ampersand is a middle market private equity firm
dedicated to growth-oriented investments in the healthcare sector.
Ampersand leverages its unique blend of private equity and operating
experience to build value and drive superior long-term performance
alongside its portfolio company management teams. Ampersand has helped
build numerous market-leading companies across each of our core
healthcare sectors, including Avista Pharma, Brammer Bio, Confluent
Medical, Genoptix, Talecris Biotherapeutics and Viracor-IBT
Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.

Contacts

BAERING
Jordan Watkins, 919-233-6600
[email protected]